🇺🇸 FDA

Intelligence · Patent portfolio

Vanda Pharmaceuticals Netherlands Patents

Full USPTO pharma patent portfolio for Vanda Pharmaceuticals Netherlands — grant dates, expiration, and drug cross-links.

Patents
96
Expiring ≤24m
0

Quick answer

Vanda Pharmaceuticals Netherlands has 96 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 2

  1. US 12427132

    Method of improving sleep

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12419869

    Methods of treating multiple sclerosis

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12403134

    Method for improving or enhancing cognition

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12357616

    Methods of treating multiple sclerosis

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12318375

    Method of treatment with tradipitant

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12201604

    Treatment of circadian rhythm disorders

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12049457

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11951097

    Methods of treating multiple sclerosis

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11918556

    Treatment of circadian rhythm disorders

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11918557

    Treatment of circadian rhythm disorders

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11850229

    Treatment of circadian rhythm disorders

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11845990

    Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11833130

    Treatment of circadian rhythm disorders

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11826339

    Treatment of circadian rhythm disorders

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11786502

    Method of treatment

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11760740

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11759446

    Liquid tasimelteon formulations and methods of use thereof

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11737993

    Multiple myeloma treatment

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11723903

    Treatment of schizophrenia

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11667718

    Cancer treatment

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11633377

    Treatment of circadian rhythm disorders

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11607408

    Method of treatment of schizophrenia

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11566011

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11549147

    Treatment of atopic dermatitis with tradipitant

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11458116

    Method of improving sleep

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11458154

    Treatment of CYR61- and VEGF-mediated conditions

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11433057

    Method for improving or enhancing cognition

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11324735

    Method of treatment with tradipitant

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11285129

    Treatment of circadian rhythm disorders

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11266622

    Method of treatment

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11202770

    Liquid tasimelteon formulations and methods of use thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11203581

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11141400

    Method of treatment

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11090285

    Treatment of circadian rhythm disorders

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11078289

    Cancer treatment

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11071728

    Treatment of schizophrenia

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11060144

    Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11013713

    Method of treatment

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10987346

    Iloperidone for the treatment of schizophrenia

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10980770

    Treatment of circadian rhythm disorders

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10945988

    Treatment of circadian rhythm disorders

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10874659

    Iloperidone metabolite for use in the treatment of psychiatric disorders

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10829465

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10821099

    Use of tradipitant in motion sickness

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10772880

    Method of treatment with tradipitant

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10653665

    Method of treatment

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vanda Pharmaceuticals Netherlands have?

96 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vanda Pharmaceuticals Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.